Caribou Biosciences Q2 net loss narrows
CRBU•Q2 results and cost cuts
Caribou Biosciences said its second-quarter licensing revenue fell year over year, while its net loss narrowed.
The US genome-editing biopharma said it reduced research and development as well as general and administrative expenses due to workforce cuts and pipeline prioritization.
Cash outlook and clinical plans
The company said its cash position is expected to fund operations through the end of 2027, including key clinical trials.
Caribou expects to report initial CB-011 dose expansion data in the second half of 2026 and said it is exploring options to fully fund the planned ANTLER-3 pivotal phase 3 trial.
Clinical data update and analyst view
Caribou said new phase 1 data for vispa-cel and CB-011 showed durable, deep responses in lymphoma and myeloma patients, supporting continued clinical development.
The current average analyst rating on the shares is "buy," with 8 "strong buy" or "buy" ratings, no "hold" ratings and no "sell" or "strong sell" ratings. The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Caribou Biosciences, Inc. is $10.50, about 517.6% above its August 12 closing price of $1.70.
